In registered ruminant flukicide programmes, Bromophenophos (Acidlist) Veterinary Grade API is directed into oral non-sterile manufacturing lines, where the organophosphate ester’s hydrolytic sensitivity and low aqueous solubility influence formulation design more than the downstream equipment class itself. The active is routinely released against a minimum assay of 98.0% on the dried basis by HPLC area normalisation, with total related substances controlled at or below 1.0%, residual solvents assessed under VICH GL18 and ICH Q3C, and sulfated ash maintained at no more than 0.1%. Because bromophenophos is a cholinesterase-inhibiting fasciolicide, closed transfer systems, dedicated dispensing rooms, and separation from other organophosphate actives are standard industrial hygiene controls. The following downstream scenarios cover orally administered presentations; published dossier depth for parenteral use in food-producing species is limited, and injection is not treated as an established global production route in this application section.

In cattle and sheep oral drench manufacturing, Bromophenophos is dispersed in non-ionic solvent-surfactant carriers because the API does not form a thermodynamically stable aqueous solution at the working concentration range. Formulation addition ratios for field-ready oral drenches commonly sit between 2.5% w/v and 7.5% w/v bromophenophos, with propylene glycol at 10–20% w/v, polysorbate 80 at 0.5–2.0% w/v, and a buffered vehicle maintained at pH 5.5–7.0. Before wetting, the API is air-jet milled to a volume median diameter of 10–25 µm, confirmed by laser diffraction under ISO 13320. Production is executed in a jacketed stainless steel vessel connected to a bottom-entry rotor-stator disperser running at 3,000–6,000 rpm; jacket coolant is held at 10–15°C to counter shear-induced temperature rise, and recirculation through a 50 µm inline screen removes coarse undispersed particles before filling. The process meets non-sterile liquid uniformity requirements under Ph. Eur. 2.9.40 or USP <905> where the registration file requires, and bottling into 1 L, 2.5 L, and 5 L high-density polyethylene packs with oral dosing gun compatibility is the terminal presentation. Operational boundary: holding tanks above pH 8.0 are avoided because organophosphate hydrolysis is alkaline-accelerated; batch records also limit product contact times above 40°C during dispersion to reduce related-substance formation.

What Happens When Bromophenophos Enters a High-Shear Feed Premix Line?

Medicated feed intermediates containing bromophenophos are manufactured as low-moisture powders or granules for further dilution in licensed feed mills, and the regulatory boundary is not API purity alone but the homogeneity of the minor component under EU Regulation 2019/4 and the sampling framework of ISO 6497:2005. In an intermediate premix, the API addition ratio typically ranges from 5% w/w to 15% w/w; after dilution at the feed mill, the finished ration is adjusted to the approved daily intake for the target species rather than to a single fixed global concentration. Production uses a horizontal ribbon mixer or paddle mixer with a working volume of 1,000–5,000 L and a mixing time of 10–20 min after an initial geometric dilution of the API through wheat middlings or calcium carbonate carrier. The carrier is specified with loss on drying below 12% w/w and sufficient oil absorption capacity to retain the API on particle surfaces; a 500 µm swept screen prevents agglomerate carryover. Terminal products include 20 kg and 25 kg multiwall paper sacks with inner polyethylene liner, as well as bulk flexible intermediate containers for licensed compounders. Feed-mill scale-up data indicate that hygroscopic carriers raise bromophenophos hydrolysis risk at ambient humidity, so the release boundary is set at residual moisture not more than 2.0% by Karl Fischer titration before bagging.

Direct compression lines for veterinary tablets expose bromophenophos to mechanical shear but avoid aqueous granulation binders that can initiate surface hydrolysis before the drying endpoint is reached. The working addition ratio in finished core tablets usually lies between 15% w/w and 40% w/w, corresponding to registered dose strengths commonly within 250–600 mg per unit depending on the species label. The powder blend is prepared by low-shear mixing in a bin blender at 10–15 rpm for 15–25 min with microcrystalline cellulose, croscarmellose sodium at 2–5% w/w, magnesium stearate at 0.5–1.0% w/w, and a moisture-protective film-coating system applied after compaction. Compression is performed on a rotary press with D-tooling at 12–25 kN main compression force and 15–30 rpm turret speed; tablet friability is controlled to not more than 1.0% according to Ph. Eur. 2.7.7, while disintegration is evaluated under Ph. Eur. 2.9.1 in water at 37 ± 2°C. Terminal presentations are 6, 12, and 100 count HDPE jars or PVC/aluminium blister packs, with desiccant sachets in markets where ambient humidity exceeds 60% RH. When the same dry blend is filled into hard capsules in smallholder markets, the process is maintained under identical humidity limits; however, published regulatory dossier depth for bromophenophos capsules is less extensive than for drench and premix routes, so formulation work is driven by local marketing authorisation requirements rather than by a harmonised global monograph annex.

Granule Friability, Residual Moisture, and the Limits of In-Feed Distribution

Granulated bromophenophos premixes are produced for farm-level mixing where dust containment is critical and where particles must disperse uniformly without segregation during auger transfer. The addition ratio in the granulated intermediate is typically 3–8% w/w active, diluted before final feed application to a ration-level concentration that depends on planned daily intake and species-specific prescription; a fixed ration-level value is not used across sheep, cattle, and goat feeds because intake rates differ. The granulation step uses a top-spray fluid-bed process with inlet air temperature 55–70°C, product temperature maintained at 30–40°C, spray rate 80–150 g/min per kg of dry charge, and a binder solution containing 5–10% w/w polyvinylpyrrolidone or pregelatinised starch. After drying, granules are screened through 1.0 mm and 0.25 mm sieves to control the size distribution under ISO 9276-1; fine particles below 0.25 mm are limited to 10–15% w/w to reduce dust and bridging. The terminal product is packed at residual moisture below 2.0% w/w by Karl Fischer titration and must meet internal friability limits before release. Feed-mill trials demonstrate that granulate bulk density in the range 0.55–0.75 g/cm³ is preferable for consistent flow through volumetric screw feeders; outside this range, single-auger dosing accuracy to ±1% becomes difficult under high-throughput conditions.

Because bromophenophos has limited direct dissolution in hard water, on-farm water-medication formulations are manufactured as dry, partly acidified powders rather than as simple micronised API slurries. The formulation ratio in the finished drinking-water powder generally falls between 10% w/w and 30% w/w bromophenophos, with anhydrous citric acid at 5–10% w/w, lactose monohydrate or dextrose carrier, and a water-soluble polymer binder to support dispersion. The manufacturing route is dry blending in a V-type or bin blender at 5–10 rpm for 20–30 min, followed by filling into 100 g to 1 kg aluminium foil sachets. A release test for dispersion is executed by adding the powder to 10 L of potable water at 20–25°C under continuous stirring for 10 min; the resulting drench-water suspension is then passed through a 180 µm sieve to confirm the absence of lumps. Terminal product types are sachets and water-soluble pouches intended for single-day administration under veterinary supervision. Water hardness above 250 mg/L calcium carbonate equivalent is an operational boundary; high bicarbonate concentrations reduce the acid buffer capacity and may slow dispersion, so local water quality data should be included in batch record verification before product release.

When a Drench Concentrate Exceeds 10% w/v, Phase Separation Moves From Risk to Failure

High-load liquid formulations are examined separately because the solubility-adjuvant ratio does not scale linearly beyond the midpoint of the working range. At attempted bromophenophos loadings above 10% w/v, sedimentation volume and redispersibility are evaluated under in-house non-sterile liquid protocols referencing ICH Q1A and VICH GL3; no harmonised monograph limit defines the upper concentration, so the working addition ratio is capped at 10% w/v unless pre-formulation data support a co-solvent system. If a co-solvent is required, propylene glycol is increased to 20–30% w/v and viscosity is monitored at 25°C using a rotational viscometer spindle 2 at 50 rpm. The production process for high-load drench concentrates uses a jacketed stainless steel mixing vessel with a top-entry propeller and a bottom homogeniser; homogenisation at 3,000 rpm lasts 20–30 min, followed by cooling to 15–20°C before adjustment of the continuous phase. Stability evaluation follows ICH Q1A and VICH GL3 bracketing protocols for non-sterile liquids, with six-month accelerated storage at 40°C ± 2°C / 75% RH ± 5% RH and twelve-month intermediate storage at 30°C ± 2°C / 65% RH ± 5% RH. Terminal pack presentations are 500 mL, 1 L, and 5 L high-density polyethylene containers with high-torque screw caps. Published data for this specific high-load configuration are limited in some jurisdictions; therefore the registration file is generated from in-house forced degradation and compatibility data rather than from a harmonised monograph annex.